Latest Conference Articles

April 10th 2021, 12:30pm

AACR Annual Meeting

The CDK9 inhibitor voruciclib demonstrated early activity as a single agent in KRAS-mutant cancer cell lines, and synergistically inhibited growth of KRAS-mutant cancers when used in combination with sotorasib and adagrasib in preclinical models.

April 10th 2021, 12:30pm

AACR Annual Meeting

Tebentafusp (IMCgp100) resulted in a highly significant and clinically meaningful improvement in overall survival when given as a frontline treatment in patients with metastatic uveal melanoma.

April 10th 2021, 12:30pm

AACR Annual Meeting

Neoadjuvant treatment with nivolumab combined with chemotherapy led to a significant improvement in pathologic complete response compared with chemotherapy alone in patients with resectable non–small cell lung cancer.

March 30th 2021, 12:30pm

PER® Miami Breast Cancer Conference

Faculty from the Miami Breast Cancer Conference® discuss how to apply the RxPONDER data to clinical practice.

March 29th 2021, 10:11pm

School of Gastrointestinal Oncology

Axel Grothey, MD, discusses the differences between available assays evaluating circulating tumor DNA in colorectal cancer.

March 29th 2021, 8:04pm

SGO Annual Meeting

The combination of mirvetuximab soravtansine and rucaparib was found to be well tolerated, with encouraging activity reported in heavily pretreated patients with endometrial, ovarian, fallopian tube, or primary peritoneal cancer.

March 28th 2021, 10:00am

HCC-TAG Conference

A regimen comprised of a single 300-mg priming dose of tremelimumab and 1500 mg of durvalumab every 4 weeks yielded favorable efficacy and an acceptable safety profile in patients with advanced HCC.

March 27th 2021, 4:45pm

European Lung Cancer Congress

Suresh S. Ramalingam, MD, FASCO, deputy director, director, Lung Cancer Program, Winship Cancer Institute of Emory University, professor, assistant dean, Roberto C. Goizueta Distinguished Chair for Cancer Research, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine, discusses treatment after osimertinib (Tagrisso) in EGFR-mutant non–small cell lung cancer (NSCLC).

March 27th 2021, 2:53pm

European Lung Cancer Congress

More patients with stage III non–small cell lung cancer received sequential chemoradiation and delayed the time to durvalumab treatment in a real-world setting compared with those enrolled on the phase 3 PACIFIC trial.

March 27th 2021, 1:57pm

European Lung Cancer Congress

Osimertinib (Tagrisso) showcased encouraging efficacy and acceptable safety in patients with EGFR-positive, advanced non–small cell lung cancer. according to real-world findings from an observational, multicenter study.

March 26th 2021, 11:25pm

HCC-TAG Conference

Although the combination of atezolizumab and bevacizumab has become the standard frontline treatment for patients with advanced hepatocellular carcinoma, whether immunotherapy could play a role in earlier lines of treatment remains the subject of ongoing research.

March 26th 2021, 11:13pm

HCC-TAG Conference

Combinations of checkpoint inhibitors and VEGF TKIs, as well as dual checkpoint blockade, are affording patients with advanced hepatocellular carcinoma greater potential for disease control and deep, long-lasting responses, underscoring the need for biomarkers of response to combination regimens and single-agent TKIs, the latter of which still play a role for select populations.

March 26th 2021, 10:58pm

European Lung Cancer Congress

Andrew G. Robinson, MD, MSc, FRCPC, discusses the updated results of the phase 3 KEYNOTE-407 trial in squamous non–small cell lung cancer.

March 26th 2021, 10:54pm

European Lung Cancer Congress

Lyudmila A. Bazhenova, MD, discusses the results of a preliminary exploratory correlative analysis of the phase 1/2 KRYSTAL-1 trial in advanced non–small cell lung cancer.

March 26th 2021, 10:25pm

European Lung Cancer Congress

Treatment with chemotherapy plus immunotherapy did not demonstrate significant clinical benefit over chemotherapy alone in patients with EGFR-mutated non–small cell lung cancer after progression on osimertinib.

March 26th 2021, 10:23pm

European Lung Cancer Congress

Previous exposure to immune checkpoint inhibitors or osimertinib has been linked with poor outcomes in patients with non–small cell lung cancer who were receiving a subsequent atezolizumab-containing regimen.

March 26th 2021, 9:00pm

HCC-TAG Conference

Amit Singal, MD, discusses downstaging strategies for patients with hepatocellular carcinoma.

March 26th 2021, 8:35pm

European Lung Cancer Congress

The half-life extended, DLL3-targeting bispecific T-cell engager AMG 757 demonstrated early signals of efficacy and a favorable safety profile in patients with small cell lung cancer.

March 25th 2021, 9:55pm

European Lung Cancer Congress

Adagrasib yielded durable responses and broad disease control, in addition to providing extensive predicted coverage throughout the dosing interval, in patients with KRAS G12C–mutant advanced non–small cell lung cancer.

March 25th 2021, 9:31pm

European Lung Cancer Congress

Marina Chiara Garassino, MD, discusses the rationale for the phase 2 PACIFIC-6 trial in non–small cell lung cancer.